Revolutionizing Gut Health with Biotechnology
Pioneering advanced biotech solutions to enhance gut-brain health,
Viholabs combines innovation with scientific excellence for optimal well-being.
Mastering Brain Gut Axis
Optimizing Brain Wellness Through Gut
At VihoLabs®, we revolutionize healthcare with innovative OTX solutions, specializing in the Gut/Brain Axis to redefine chronic disease management. Our mission is to enhance quality of life by addressing unmet medical needs, including complications from oncology and diabetes treatments. Discover the future of health with VihoLabs®.
Focus on High Potential and Opportunity Markets
Viholabs focuses on high potential and opportunity markets, specifically those derived from the Gut-Brain Axis and related to our product lines, both in the market and in development. These markets represent areas with significant demand for innovative solutions, where Viholabs leverages its advanced technology and expertise to create a positive impact.
Technological Development
Viholabs’ SynchroAxis technology not only focuses on creating high-quality products but also drives innovation in the healthcare field. The ability to tailor treatments to patients’ biological rhythms makes a crucial difference in their effectiveness. This translates to tangible improvements in health outcomes and a reduction in side effects, setting a new standard in medical care.
SynchroAxis represents a significant advancement in the formulation and production of products for human health. This technology is based on the precise synchronization of circadian rhythms and the individual pathophysiological needs of each patient. By considering these factors, SynchroAxis optimizes the absorption and efficacy of active ingredients, providing unique treatments on the market that are more personalized and effective.
SynchroAxis represents a groundbreaking shift in healthcare, creating more personalized and effective treatments for improved health outcomes.
Leading and creating the only Monopoly of Value
in the Gut-Brain Axis.
VihoLabs is the only company with a differential approach in the prevention and treatment of pathologies associated with the Gut-Brain Axis
Digestive Pathologies
Digestive pathologies (IBS, Chron, SIBO, etc.) affect more than 1.5 billion people worldwide, and digestive system dysfunctions are the basis of many other chronic conditions.
A market valued at more than 51 billion USD, waiting for innovative solutions, which Viholabs has developed through a unique technological approach.
Overweight and Obesity
Overweight and obesity are a global public health problem, affecting 39% of the population. It is one of the fastest growing markets in the health sector globally, a market valued at 77 billion USD.
Viholabs takes a unique approach to this market, with products offering enormous differential value, designed to lead this market in an effective and safe way.
Neurodegenerative Diseases and Neuropsychiatry
Diseases like Alzheimer’s, Parkinson’s, and depression affect over 30% of the global population. Viholabs provides innovative products for prevention and treatment.
A market worth over 90 billion USD, driven by the demand for our solutions.
Comprehensive Health Monitoring
We develop effective and safe solutions that promote healthy longevity. Our products enhance vitality and quality of life in maturity, meeting the demand for healthy aging treatments.
With our SynchroAxis technology, we support inner beauty and health, improving well-being for a more active and fulfilling life.
Revolutionizing Gut-Brain Approach
We focus on developing products that improve gut function and immune balance, positively impacting the mental and emotional health of patients.
Disorders such as:
- Irritable Bowel Syndrome (IBS)
- Inflammatory Bowel Disease (IBD)
- Anxiety and depression disorders
- Neurological and neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and multiple sclerosis
These areas represent a high potential market due to the increasing incidence of these disorders and the demand for more effective and personalized treatments.
Obesity
GLP-1 receptor agonists (such as Ozempic, Wegovy, etc.) are gaining popularity, but their availability for healthy individuals dealing with excess weight is limited, and they come with significant side effects.
Market Insights:
– The global GLP-1 analogues market was valued at $47.4 billion in 2024 and is projected to reach $471.1 billion by 2032, growing at a CAGR of 33.2% from 2024 to 2032.
– Over 50% of the global population struggles with overweight or the sensation of excess weight, but most are unable to legally access prescriptions for GLP-1 receptor agonists.
This massive market presents an opportunity, and Viholabs, with its unique approach, emerges as the ultimate solution.
Connect with Our Experts
Bac de Roda, 63. 08005 Barcelona